Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
## Adult Dosing
* **Erosive esophagitis:** 40 mg orally once daily for up to 8 weeks.
* **Maintenance of healing:** 40 mg orally once daily.
* **Pathological hypersecretory conditions:** Starting dose 40 mg orally twice daily, may be increased to 40 mg up to 3 times daily. Doses higher than 40 mg twice daily should be administered with caution and only if clinically indicated. Maximum daily dose is 120 mg.
## Pediatric Dosing
* **Erosive esophagitis (ages 5-16 years):** 20 mg orally once daily for up to 8 weeks.
* **Erosive esophagitis (ages 1 month to <5 years):** Dosing varies based on weight. Consult specific pediatric guidelines or prescriber. Dosing is typically 1 mg/kg/day to 1.3 mg/kg/day, divided into two doses. Maximum dose is 40 mg daily.
## Dose Adjustments
No dose adjustment is typically required for renal impairment.
For severe hepatic impairment, the recommended dose is 20 mg orally once daily.
## Contraindications
* Hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
Common: Headache, diarrhea, nausea, abdominal pain, flatulence, dizziness.
Serious: Clostridium difficile-associated diarrhea, bone fractures (hip, wrist, spine), hypomagnesemia, lupus erythematosus cutaneus, vitamin B12 deficiency.
## Key Drug Interactions
* **Drugs dependent on gastric pH for absorption:** Ketoconazole, itraconazole, iron salts, digoxin, mycophenolate mofetil. Reduced absorption may occur.
* **Methotrexate:** Concomitant use may increase methotrexate levels, potentially leading to toxicity. Monitor and consider dose reduction of methotrexate.
* **CYP2C19 Substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Consider potential interactions with drugs metabolized by this enzyme (e.g., clopidogrel, although clinical significance is debated).
## Monitoring
* Monitor for symptoms of gastrointestinal bleeding or ulceration.
* Consider monitoring magnesium levels, especially with long-term use (>3 months) or when co-administered with digoxin or diuretics.
* Monitor for signs of bone fracture with long-term use.
* Assess for diarrhea, particularly C. difficile-associated diarrhea.
## Clinical Pearls
* Administer pantoprazole 30 minutes before a meal.
* Oral suspension should be taken immediately after preparation.
* Long-term PPI use is associated with increased risk of fractures, C. difficile infection, hypomagnesemia, and vitamin B12 deficiency. Use the lowest effective dose for the shortest duration necessary.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional protocols for definitive patient management decisions.
